Among the solid tumors that oncologists dread, pancreatic ductal adenocarcinoma (PDAC) holds a special place. Its five-year survival rate hovers around 12%. Its dominant driver mutation — KRAS — was for decades considered “undruggable.” Standard second-line chemotherapy extends life by weeks, not months, and comes with toxicity that many patients struggle to tolerate.
On May 31, at the ASCO 2026 plenary session, a team led by Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute presented data that changed the arithmetic. The drug is daraxonrasib (RMC-6236), an oral RAS(ON) multi-selective inhibitor from Revolution Medicines. The RASolute 302 trial randomised 500 patients with previously treated, RAS-mutated metastatic PDAC to either daraxonrasib or physician’s choice of chemotherapy. The results, published simultaneously in the New England Journal of Medicine, were striking enough that several independent experts reached for sports metaphors.
“In the RAS G12 population — about 80% of the trial — median overall survival was 13.2 months on daraxonrasib versus 6.6 months on chemotherapy,” Wolpin reported from the podium. The hazard ratio for death was 0.40 (p = 5.9 × 10⁻¹⁰), meaning a 60% reduction in the risk of death at any given time. The benefit was consistent across all RAS mutation subtypes, including G12X, G13X, and Q61 variants. In the overall intention-to-treat population, the hazard ratio was identical at 0.40 (p = 4.6 × 10⁻¹¹).
Progression-free survival told the same story: 7.3 months versus 3.5 months in the RAS G12 population (HR 0.45, p = 3.2 × 10⁻⁹). Objective response rates — tumour shrinkage of 30% or more — were 33.2% on daraxonrasib versus 11.8% on chemotherapy.
Rachna Shroff, MD, chief of oncology at the University of Arizona Cancer Center and an independent discussant, told the audience: “Having treated pancreatic cancer for 16 years, I actually started crying in clinic. These results are landscape-changing.” Julie Gralow, MD, ASCO’s chief medical officer, called it “a grand slam.”
How daraxonrasib works
The mechanism matters for understanding why this trial succeeded where so many failed. Daraxonrasib is a molecular glue: it binds to the abundant intracellular protein cyclophilin A, forming a binary complex that then captures active RAS proteins in their GTP-bound “ON” state. This tri-complex blocks downstream signaling through the MAP kinase and PI3K pathways that drive proliferation and survival.
Crucially, daraxonrasib is not selective for a single KRAS mutation. It covers G12, G13, and Q61 mutant forms as well as wild-type RAS — making it suitable for the broad PDAC population, where KRAS G12D and G12V together account for roughly 80% of cases. This breadth is what gave the trial its statistical power; the investigators did not need to screen for a narrow genetic subset.
The design builds on earlier work. An earlier Phase 1/2 portion of the same trial, involving 168 patients and published in the same NEJM paper, established the 300 mg once-daily dose and showed an objective response rate of approximately 30% in second-line patients.
Safety: better tolerated than chemotherapy
The tolerability profile deserves attention. Grade 3 or higher treatment-related adverse events occurred in 43.6% of patients on daraxonrasib, compared with 57.5% on chemotherapy. More tellingly, only 1.2% of patients discontinued daraxonrasib due to side effects, versus 11.2% in the chemotherapy arm.
The most common side effect is rash — affecting roughly 90% of patients to some degree, with about 14% experiencing grade 3 rash that typically starts on the face and can spread to the scalp, chest, and back. The investigators report it is manageable with topical steroids and oral antihistamines. Other common effects include stomatitis, nausea, diarrhea, and fatigue.
Patient-reported outcomes also favored daraxonrasib, with significantly delayed time to deterioration in pain and global health status.
What this means — and what it doesn’t
Anirban Maitra, MBBS, a pancreatic cancer researcher at NYU Langone Health, offered a characteristic note of caution: “This is not a panacea. We have not cured pancreas cancer. I cannot emphasize this enough.”
He is right. Median survival of 13.2 months, while dramatically improved over 6.6 months, still represents a disease that is ultimately fatal for the vast majority of patients. The trial enrolled second-line patients — those whose cancer had already progressed on first-line FOLFIRINOX or gemcitabine-based therapy. The 12-month overall survival rate on daraxonrasib was 53.3%; on chemotherapy it was 18.7%. A meaningful gain, but not a cure.
Several questions remain open:
- Duration of benefit — How durable are responses beyond the median? The data cutoff was February 10, 2026, and longer follow-up is needed.
- First-line and adjuvant use — Trials are already underway: RASolute 303 in first-line and RASolute 304 in the adjuvant setting.
- Cost and access — Revolution Medicines has not disclosed pricing. The company’s market capitalization exceeds $30 billion on the strength of these data.
- Resistance — As with all targeted therapies, resistance mechanisms will emerge. Combination strategies with chemotherapy, immunotherapy, or other RAS pathway inhibitors are logical next steps.
The FDA has already granted expanded access to daraxonrasib as of May 1, 2026, signaling likely regulatory approval. Wolpin told reporters: “Were this drug to be approved, it would mark a dramatic shift in how pancreatic cancer is treated.”
The sober bottom line
The RASolute 302 trial is the first positive Phase 3 study of a RAS-targeted therapy in pancreatic cancer — a disease where every previous attempt to inhibit this pathway had failed. The hazard ratio of 0.40 for overall survival, the consistency across mutation subtypes, and the superior tolerability relative to chemotherapy all point to a new standard of care for second-line PDAC.
But the language of “breakthrough” and “game-changer,” while emotionally understandable, needs to be held against the reality that median survival remains just over a year. As Maitra put it: “It’s a major home run. We haven’t won the World Series, but it’s a home run in a disease where there has been a series of strikeouts.”
The Ras revolution has reached pancreatic cancer. The next chapters — how to combine, sequence, and extend these gains — are already being written.
Sources:
- Wolpin BM et al. “Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.” New England Journal of Medicine, Vol. 394, May 6, 2026, p. 1790. DOI: 10.1056/NEJMoa2505783
- ClinicalTrials.gov: NCT05379985 (RASolute 302)
- Rosen M. “A new pancreatic cancer pill may be a game changer for patients.” Science News, May 31, 2026
- Gregory A. “Daily pill can double survival time for world’s deadliest cancer, trial shows.” The Guardian, May 31, 2026
- Feuerstein A. “‘Stunning results’ for Revolution Medicines pancreatic cancer drug.” STAT News, May 31, 2026
- ASCO 2026 Plenary Session, Abstract LBA5